EU Panel Grants Positive Opinion to Brigatinib for ALK+ NSCLC

September 21, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended full approval of brigatinib as a treatment for patients with advanced ALK-positive non–small cell lung cancer (NSCLC) who are previously treated with crizotinib. The recommendation is based on data from the phase II ALTA trial, which showed that the objective response rate (ORR) was 56% for those who received brigatinib … (leggi tutto)